Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Closing remarks and treatment guidelines.

M Piccart1

  • 1Institut Jules Bordet, Unité de Chimiotherapie, 1 Rue Héger Bordet, B-1000, Brussels, Belgium

European Journal of Cancer (Oxford, England : 1990)
|May 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.

ESMO open·2025
Same author

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance.

ESMO open·2025
Same author

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Oncogene·2025
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

HER2 testing is crucial for breast cancer management. Accurate HER2 status determination guides treatment decisions, especially with targeted therapies like trastuzumab.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The human epidermal growth factor receptor 2 (HER2) is a key membrane receptor involved in cellular growth.
  • HER2 plays a significant role in breast cancer biology.
  • Targeting HER2 has emerged as a critical strategy in breast cancer treatment.

Purpose of the Study:

  • To highlight the importance of HER2 status in breast cancer patient management.
  • To emphasize the need for standardized and refined HER2 testing methods.
  • To discuss the clinical implications of HER2 positivity in light of emerging therapies.

Main Methods:

  • Review of existing literature and clinical trial data (1999-2000).
  • Analysis of the role of HER2 in breast cancer pathogenesis.

Related Experiment Videos

  • Incorporation of data from prospective trials on trastuzumab efficacy.

    • Main Results:

    • Trastuzumab (Herceptin) has demonstrated survival benefits in metastatic HER2-positive breast cancer.
    • HER2 status directly impacts optimal breast cancer management strategies.
    • Current HER2 testing faces challenges in standardization and reproducibility.

    Conclusions:

    • HER2 testing is essential and should not be overlooked in breast cancer care.
    • Refining and standardizing HER2 testing is a high priority to minimize false negatives and improve reliability.
    • HER2-positive status has significant implications for clinical practice and treatment algorithms.